Biond is developing a cutting-edge pipeline of biological first-in-class immunotherapies.
Biond’s pipeline features first-in-class shedding blockers that modulate key pathological pathways in oncology and autoimmune disease, alongside innovative Immuno-Oncology (IO) assets targeting novel mechanisms within the tumor microenvironment.
